Organizations Filed Purposes:
THE PRIMARY EXEMPT PURPOSE OF MICROBIOME HEALTH RESEARCH INSTITUTE, INC. (ALSO KNOWN AS OPENBIOME) IS TO EXPAND SAFE ACCESS TO FECAL MICROBIOTA TRANSPLANTATION AND TO CATALYZE RESEARCH INTO THE HUMAN MICROBIOME.
ENFORCEMENT DISCRETION PROGRAM: OPENBIOME SEEKS TO ELIMINATE THE PRACTICAL BARRIERS TO FECAL MICROBIOTA TRANSPLANTATION (FMT) FOR THE TREATMENT OF RECURRENT C. DIFFICILE INFECTION. OPENBIOME AIMS TO ENSURE THAT THOSE WHO NEED FMT HAVE SAFE, CONVENIENT, AND AFFORDABLE ACCESS TO THE TREATMENT THROUGH THEIR PHYSICIAN. UNDER THE FDAS ENFORCEMENT DISCRETION RULING FOR FMT, WE STRIVE TO MAKE THE PATH TO TREATMENT AS SIMPLE AS POSSIBLE FOR PATIENTS AND THEIR DOCTORS, WHILE BRINGING A LEVEL OF SAFETY AND STANDARDIZATION TO THE PROCESS THAT HAS SET THE STANDARD FOR THIS EMERGING FIELD. OPENBIOME PROVIDES RIGOROUSLY SCREENED, READY-TO-USE FECAL MICROBIOTA PREPARATIONS SO THAT PHYSICIANS CAN DEVOTE THEIR TIME AND ENERGY TO TREATING PATIENTS, RATHER THAN THE COMPLEXITIES OF MANAGING A STOOL DONOR PROGRAM.
CLINICAL RESEARCH PROGRAM: OPENBIOME SEEKS TO ENABLE TRANSLATIONAL RESEARCH ON THE HUMAN MICROBIOME. TO DO SO, WE PROVIDE A SUITE OF SERVICES TO HELP INVESTIGATORS UNCOVER THE ROLE OF THE GUT MICROBIOME IN HUMAN HEALTH, AND TO DISCOVER HOW ENGINEERING IT CAN DRIVE BETTER HEALTH OUTCOMES. OUR SERVICES INCLUDE THE PROVISION OF CUSTOMIZED FECAL MICROBIOTA PREPARATIONS, STUDY DESIGN AND REGULATORY SUPPORT FOR CLINICAL TRIALS, AND BIOINFORMATICS AND ANALYTICAL SERVICES. OPENBIOME ALSO SPONSORS ITS OWN STUDIES INVESTIGATING CRITICAL MICROBIOME-RELATED HEALTH CONDITIONS.
Executives Listed on Filing
Total Salary includes financial earnings, benefits, and all related organization earnings listed on tax filing
| Name | Title | Hours Per Week | Total Salary |
|---|
| Steven Weinstein | INTERIM COO | 40 | $266,142 |
| Majdi Osman Md | CLINICAL PROGRAM DIRECTOR | 40 | $157,273 |
| Jeannette Van Der Velde | VICE PRESIDENT OF RESEARCH | 40 | $131,316 |
| James Sigler | EXEC. VP, CMC & SITE HEAD | 40 | $130,847 |
| Charles Young | SR. DIR. & HEAD OF MANUFACTURING | 40 | $128,777 |
| Carolyn Edelstein | EXECUTIVE DIRECTOR | 40 | $125,000 |
| Scott Oleson Phd | SCIENTIFIC DIRECTOR | 40 | $122,420 |
| Ken Linde | DIRECTOR OF IT | 40 | $116,052 |
| Robert Rosenbaum | STRATEGIC INITIATIVES & DEVELOP. DIR. | 40 | $115,358 |
| Kathleen Gallagher | DIRECTOR OF FINANCE (UNTIL AUG 2019) | 40 | $79,808 |
| Mark Smith | DIRECTOR (UNTIL 1/14/19) | 2 | $0 |
| James Burgess | DIRECTOR (UNTIL 1/14/19) | 2 | $0 |
| Eric Alm Phd | DIRECTOR | 2 | $0 |
| Jane Williams Md Mph | DIRECTOR | 2 | $0 |
| Neil Rasmussen | DIRECTOR | 2 | $0 |
| Charles Hewett Phd | DIRECTOR | 2 | $0 |
| James Bildner | DIRECTOR/TREASURER | 2 | $0 |
| Lisa Serwin | DIRECTOR/BOARD CHAIR | 10 | $0 |
Data for this page was sourced from XML published by IRS (
public 990 form dataset) from:
https://s3.amazonaws.com/irs-form-990/202003189349303305_public.xml